Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy

被引:17
作者
Jessen, Christian [1 ]
Agerbaek, Mads [1 ]
Von Der Maase, Hans [1 ]
机构
[1] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark
关键词
ADVANCED BLADDER-CANCER; UROTHELIAL CANCER; GEMCITABINE; METHOTREXATE; COMBINATION; TUMORS; TRIAL; VINBLASTINE; DOXORUBICIN; PACLITAXEL;
D O I
10.1080/02841860802325932
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The study was undertaken to identify pre-treatment clinical and histopathological factors of importance for response and survival after cisplatin-based combination chemotherapy, in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium. Patients and methods. Clinical, laboratory and histopathological data from 178 consecutive patients, representing all patients treated between 1991 and 2001 in a single institution, were collected. Correlations between these data and response and survival after chemotherapy were analysed using univariate and multivariate analyses. Results. Absence of visceral metastasis was the only parameter with independent correlation to the response to chemotherapy. Two of the analysed parameters were independently associated with increased survival: good performance status (PS1) and absence of visceral metastases. Stratification of the patient material according to number of these risk-factors present showed strong association with survival. Conclusion. It was possible to predict survival from pre-treatment clinical parameters and consequently it is possible to select groups with a high and low probability of obtaining long term survival following cisplatin-containing chemotherapy.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 24 条
[21]   Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study [J].
von der Maase, H ;
Hansen, SW ;
Roberts, JT ;
Dogliotti, L ;
Oliver, T ;
Moore, MJ ;
Bodrogi, I ;
Albers, P ;
Knuth, A ;
Lippert, CM ;
Kerbrat, P ;
Rovira, PS ;
Wersall, P ;
Cleall, SP ;
Roychowdhury, DF ;
Tomlin, I ;
Visseren-Grul, CM ;
Conte, PF .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3068-3077
[22]   Current and future perspectives in advanced bladder cancer: Is there a new standard? [J].
von der Maase, H .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :3-14
[23]   Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium:: A phase II clinical trial [J].
von der Maase, H ;
Andersen, L ;
Crinò, L ;
Weinknecht, S ;
Dogliotti, L .
ANNALS OF ONCOLOGY, 1999, 10 (12) :1461-1465
[24]  
VONDERMAASE H, 2003, AM SOC CLIN ONC 39 A, V22, P410